ストックスクリーナーアプリを入手
1.61
0.62%
-0.01
プレマーケット:
1.64
0.03
+1.86%
前日終値:
$1.62
開ける：
$1.62
24時間の取引高:
192.99K
Relative Volume:
0.66
時価総額：
$48.21M
収益：
$210.70K
当期純損益:
$-21.37M
株価収益率:
-1.4636
EPS:
-1.1
ネットキャッシュフロー:
$-21.10M
1週間 パフォーマンス:
-9.04%
1か月 パフォーマンス:
-5.85%
6か月 パフォーマンス:
-29.39%
1年 パフォーマンス:
+26.77%
1日の値動き範囲:
$1.59
$1.66
1週間の範囲:
$1.5251
$1.9349
52週間の値動き範囲:
$0.89
$3.19
Gain Therapeutics Inc Stock (GANX) Company Profile
GANX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GANX
Gain Therapeutics Inc
|
1.61 | 53.00M | 210.70K | -21.37M | -21.10M | -1.10 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.27 | 123.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
550.00 | 60.43B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.69 | 42.07B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
572.71 | 34.47B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
290.35 | 27.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Gain Therapeutics Inc Stock (GANX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-07 | 開始されました | Scotiabank | Sector Outperform |
| 2024-12-06 | 開始されました | ROTH MKM | Buy |
| 2024-08-14 | 再開されました | Oppenheimer | Outperform |
| 2021-04-12 | 開始されました | BTIG Research | Buy |
| 2021-04-12 | 開始されました | Oppenheimer | Outperform |
Gain Therapeutics Inc (GANX) 最新ニュース
What analysts say about Gain Therapeutics Inc. stock outlookFree Best Stocks to Buy Today - Newser
Is Heron Therapeutics Inc. stock a good hedge against inflationDaily Gain Forecast - Newser
Gain Therapeutics Announces $7 Million Public Offering - TipRanks
Form 424B5 Gain Therapeutics, Inc. - StreetInsider
Why Gain Therapeutics Inc. stock attracts strong analyst attentionDaily Stock Radar - beatles.ru
Gain Therapeutics Announces Pricing of $7.0 Million Public Offering - The Manila Times
Gain Therapeutics on pricing stock-and-warrants offering - TradingView
Gain Therapeutics Secures $7M Funding to Advance Novel Parkinson's Treatment Pipeline - Stock Titan
US Futures Trade Mixed As June Inflation Ticks Up: ASML, Morgan Stanley, Goldman Sachs, BofA Earnings In Focus - Benzinga
Why Data Storage Shares Are Trading Higher By 35%; Here Are 20 Stocks Moving Premarket - Benzinga
Gain Therapeutics' High-Stakes Gamble: Can GT-02287 Rewrite the Neurodegenerative Treatment Playbook? - AInvest
Gain Therapeutics Plans Public Offering of Common Shares, Warrants - MarketScreener
Gain Therapeutics falls on equity offering plans - TradingView
Gain Therapeutics Announces Proposed Public Offering - The Manila Times
Gain Therapeutics stock falls after announcing public offering By Investing.com - Investing.com Canada
Gain Therapeutics stock falls after announcing public offering - Investing.com
Gain Therapeutics, Inc. Proposes Underwritten Public Offering of Common Stock and Warrants - Quiver Quantitative
Gain Therapeutics Unveils Strategic Public Offering: Funding Next-Gen Parkinson's Treatment Development - Stock Titan
Why Alaunos Therapeutics Inc. stock attracts strong analyst attentionRapid Gain Targets - Newser
How Atossa Therapeutics Inc. stock performs during market volatilityDaily Gain Forecast - Newser
How Maze Therapeutics Inc. stock performs during market volatilityDaily Gain Forecast - Newser
What makes Gain Therapeutics Inc. stock price move sharplyReturn Optimized Trade Insights - Newser
What makes Akero Therapeutics Inc. stock price move sharplyFree Access to Community - Newser
Why Sangamo Therapeutics Inc. stock attracts strong analyst attentionDaily Gain Forecast - Newser
What makes Tango Therapeutics Inc. stock price move sharplyDaily Gain Forecast - Newser
What makes Spero Therapeutics Inc. stock price move sharplyDaily Gain Forecast - Newser
How Gain Therapeutics Inc. stock performs during market volatilityMomentum Swing Watchlist - Newser
What makes Lexeo Therapeutics Inc. stock price move sharplyDaily Gain Forecast - Newser
Why Cabot Corporation stock attracts strong analyst attentionFree Step-by-Step Investment Guide - Newser
How Enliven Therapeutics Inc. stock performs during market volatilityDaily Gain Forecast - Newser
Why Design Therapeutics Inc. stock attracts strong analyst attentionFree Stock Investment Growth Plan - beatles.ru
Gain Therapeutics, Inc. (NASDAQ:GANX) Receives $8.20 Consensus Target Price from Brokerages - Defense World
Anti-GPC3 Therapies Market Gains Traction with Key Players Advancing Pipeline for Hepatocellular Carcinoma, Non-Small Cell Lung Cancer, Gastric Cancer, and Others | DelveInsight - The Malaysian Reserve
Beam Therapeutics (BEAM) Surges 5.7%: Is This an Indication of Further Gains? - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: RxSight (RXST), Gain Therapeutics (GANX) and Edwards Lifesciences (EW) - The Globe and Mail
Parkinson's Disease Pipeline Appears Robust With 130+ Key Pharma Companies Actively Working In The Therapeutics Segment Delveinsight - Menafn.com
Institutional investors are Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) biggest bettors and were rewarded after last week's US$47m market cap gain - Yahoo Finance
HC Wainwright Reaffirms Buy Rating for Gain Therapeutics (NASDAQ:GANX) - Defense World
Gain Therapeutics stock advances as Phase 1b trial enrollment exceeds expectations - Investing.com India
Gain Therapeutics Announces Completion of Target Enrollment in Phase 1b Clinical Study Evaluating GT-02287 in People With Parkinson’s Disease With or Without a GBA1 Mutation - TradingView
Viking Therapeutics, Inc. (VKTX) Stock Drops Despite Market Gains: Important Facts to Note - MSN
Gain Therapeutics Doubles Authorized Common Stock Shares - TipRanks
Gene-Editing Stocks Gain on LLY-VERV Deal Announcement - TradingView
SpringWorks Therapeutics (SWTX) Continues Strong Yearly Run, Showing Over 29% YTD Gain - Daily Chhattisgarh News
Aquestive stock gains on FDA review for allergy drug (AQST) - Seeking Alpha
Stellantis (NYSE:STLA) Receives Consensus Rating of “Hold” from Analysts - Defense World
Gain Therapeutics, Inc. (NASDAQ:GANX) Given Consensus Rating of “Buy” by Analysts - Defense World
Pharmaceutical Stocks Worth Watching – June 13th - Defense World
CRISPR Therapeutics Gains 14% in a Month: How to Play the Stock? - Yahoo Finance
Gain Therapeutics to Participate in Upcoming Investor Conferences - Bluefield Daily Telegraph
Gain Therapeutics Opens Access to Management: CEO Featured at Two Major Biotech Investor Conferences - Stock Titan
Gain Therapeutics Inc (GANX) 財務データ
収益
当期純利益
現金流量
EPS
0.64%
0.37%
大文字化:
|
ボリューム (24 時間):